Company news

Merck & Company, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)

June 12, 2026

Merck Animal Health to Acquire TARGAN

June 11, 2026

Correction: The Hashgraph Group

June 9, 2026

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

June 8, 2026

Merck &: MilliporeSigma Appoints New Heads of Discovery Solutions and Strategy & BD

June 8, 2026

Merck Appoints New Heads of Discovery Solutions and Strategy & Business Development for Life Science Business Sector

June 8, 2026

Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

June 2, 2026

FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

May 29, 2026

Merck to Participate in the Jefferies Global Healthcare Conference

May 28, 2026

Merck Announces Third-Quarter 2026 Dividend

May 26, 2026

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

May 22, 2026

MilliporeSigma Launches Supplier Sustainability Toolkits to Help Advance Supply Chain Impact

May 21, 2026

Merck Manuals Answers Common Questions About Hearing Loss and Dementia

May 21, 2026

National Advertising Review Board Refers Merck Animal Health to FTC and FDA for Bravecto Quantum Dosing Claims

May 20, 2026

Merck and eschbach's PMWS Workshop Accelerates Pharma Execution via the "Intelligent Visual Factory"

May 20, 2026

U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer

May 18, 2026

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer

May 18, 2026

KEYTRUDA Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan

May 15, 2026

The FelineVMA and Merck Animal Health Launch 2026 Scholarships to Support Future Leaders in Feline Medicine

May 13, 2026

Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026

May 12, 2026

Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate

May 7, 2026

PedvaxHIB (Merck) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

May 7, 2026

Pergonal (Merck) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

May 7, 2026

Pergoveris (Merck) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

May 7, 2026

Merck Animal Health Selects Salesforce’s Agentforce Life Sciences for Customer Engagement to Transform Animal Care and Enhance Support Experiences for Employees

May 6, 2026

Merck Completes Acquisition of Terns Pharmaceuticals, Inc.

May 5, 2026

‘1-minute’ immunotherapy jab rolled out on NHS for tens of thousands with cancer

May 3, 2026

Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones

April 30, 2026

Merck’s Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called "Bad" Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke

April 28, 2026

Gastroesophageal Adenocarcinoma Market Research Report 2026, Competitive Analysis of ALX Oncology, Merck, AstraZeneca, BeOne Medicines, Taiho Pharmaceuticals, Eli Lilly - Global Forecast to 2035

April 28, 2026

Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight

April 27, 2026

Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.

April 24, 2026

Survey Shows More Than 3 in 5 Americans Use AI Tools for Medical Information, but Most Take Steps to Check Sources and Information

April 23, 2026

Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation

April 22, 2026

FDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir)

April 21, 2026

Immuno-Oncology Drugs Market Opportunity Analysis and Forecast Report 2026-2035: Merck & Co. Remains a Dominant Force, Supported by the Commercial Success of Keytruda

April 21, 2026

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer

April 20, 2026

European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season

April 17, 2026

Soleo Health Appoints Joy Rowan as New Senior Vice President of Sales to Drive Strategic Growth Initiatives

April 16, 2026

New Survey Shows HPV Awareness Isn't Keeping Pace with Certain HPV-Related Cancer Trends in Canada

April 15, 2026

Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy

April 13, 2026

Fish Pumps Market Set to Witness Significant Growth by 2026-2033| Acuinuga, Cflow, Faivre, Merck & Co, Inc

April 10, 2026

Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.

April 7, 2026

Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration

April 2, 2026

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens

April 2, 2026

Merck Completes Acquisition of JSR Life Sciences’ Chromatography Business, Expanding Protein A Capabilities and Downstream Portfolio

April 1, 2026

Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30

April 1, 2026

Infinimmune Enters Collaboration with Merck to Discover Novel Human Antibody Therapeutics

March 31, 2026

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins

March 30, 2026

Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

March 29, 2026

← Newer news releases · Older news releases →

Calls

The 5 newest of 32 calls. Every call is listed under its year.

Decks

The 5 newest of 99 decks. Every deck is listed under its year.